A Phase 4 interventional study of RELiZORB digestive enzyme (immobilized lipase) cartridge in Acute Pancreatitis (AP) and Enhancing Enteral Nutrition Tolerance, sponsored by Northwell Health. Enrolling by invitation at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Northwell Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.
Among the 139 studies in Pancreatitis with a site in United States, this one is the 82nd largest by planned enrollment of the 97 interventional ones that give a count, is one of 9 that started in 2025, is one of 11 in phase 4, reaches primary completion later than 11 of the 48 other live ones, and was the 135th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Anna Evans Phillips · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–80
University of Southern California · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 30 · Phase 3 9 · Phase 4 11
First in 1997; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 60 across the 97 interventional studies, 433 across the 41 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 139 have an industry lead sponsor. The 10 most frequent:
Northwell Health is the lead sponsor of 476 studies on the registry; 106 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 23 (48%) have results posted.
Northwell Health has 1 study filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
18 of the studies in Pancreatitis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05252754Phase 3Johns Hopkins UniversityRectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis | 2026-12 |
| NCT06691893Phase 3Massachusetts General HospitalEvaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients | 2027-04-15 |
| NCT07583342Northwell HealthEvaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis | 2026-12 |
| NCT05659147Children's Hospital Medical Center, CincinnatiImaging Biomarkers of Pancreatic Function and Disease | 2026-12 |
| NCT06080789Panafina, Inc.A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 139 studies in Pancreatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn if Relizorb, a fat-digesting enzyme, can improve tolerance of tube feeds in adult patients with moderate to severe pancreatitis. The main question it aims to answer is:
Does Relizorb allow more nutrition to be delivered to participants than they received without it?
Participants will be observed with standard, universal monitoring after adding Relizorb to their nutrition regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with moderate to severe pancreatitis who are not tolerating sufficient enteral nutrition will have a lipase-containing cartridge (Relizorb) placed in-line with their enteral nutrition tubing, to digest the fat in the formula prior to entering the patient's intestine.
Device: RELiZORB digestive enzyme (immobilized lipase) cartridge
An in-line digestive enzyme cartridge designed for hydrolyzing lipids within enteral nutrition will be used to improve tube feed tolerance in patients with moderate to severe pancreatitis.
Percent of goal nutrition delivered at 72 hours
Change from baseline in percentage of goal enteral nutrition (kcal/kg/day) received 3 days (72 hours) following initiation of RELiZORB. Baseline is considered the 24 hours prior to RELiZORB start.
Time frame: From enrollment to the end of treatment at 72 hours
Percent of goal nutrition delivered at 24 hours
Change from baseline in goal percentage of enteral nutrition (kcal/kg/day) received 1 day (24 hours) following initiation of RELiZORB.
Time frame: From enrollment to 24 hours after starting RELiZORB
Responders at 72 hours
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 3 days (72 hours) following initiation of RELiZORB use.
Time frame: From enrollment to end of treatment at 72 hours
Responders at 24 hours
Percent of patients considered responders defined as receiving ≥80% of their daily enteral nutritional goal 1 day (24 hours) following initiation of RELiZORB use.
Time frame: From enrollment to 24 hours after starting treatment
Vomiting
Change in the number of vomiting episodes per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use
Time frame: From enrollment to completion of treatment at 72 hours
Stool volume
Change in stool volume per 24 hour period from baseline to 24 and 72 hours following initiation of RELiZORB use (if rectal tube is in place)
Time frame: From enrollment to completion of treatment at 72 hours
Bowel movements
Change in number of bowel movement episodes in 24 hours from baseline to 24 hours and 72 hours after RELiZORB (if no rectal tube)
Time frame: From enrollment to completion of treatment at 72 hours
Feeding Interruptions
Number of unplanned interruptions in tube feeding from baseline to 24 hours and 72 hours following initiation of RELiZORB use
Time frame: From enrollment to completion of treatment at 72 hours
Plan to share: No — Considering the small sample size, there is a concern for breach of confidentiality if IPD were shared.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.